Linked Life Data

20127092

Source:http://linkedlifedata.com/resource/pubmed/id/20127092

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2010-8-13
pubmed:abstractText
3-AP is a ribonucleotide reductase inhibitor and has been postulated to act synergistically with other chemotherapeutic agents. This study was conducted to determine the toxicity and antitumor activity of 3-AP with irinotecan. Correlative studies included pharmacokinetics and the effects of ABCB1 and UGT1A1 polymorphisms.
pubmed:grant
http://linkedlifedata.com/resource/pubmed/grant/1ULRR025011, http://linkedlifedata.com/resource/pubmed/grant/U01 CA062491-06, http://linkedlifedata.com/resource/pubmed/grant/U01 CA062491-07, http://linkedlifedata.com/resource/pubmed/grant/U01 CA062491-07S1, http://linkedlifedata.com/resource/pubmed/grant/U01 CA062491-07S2, http://linkedlifedata.com/resource/pubmed/grant/U01 CA062491-08, http://linkedlifedata.com/resource/pubmed/grant/U01 CA062491-09, http://linkedlifedata.com/resource/pubmed/grant/U01 CA062491-10, http://linkedlifedata.com/resource/pubmed/grant/U01 CA062491-11, http://linkedlifedata.com/resource/pubmed/grant/U01 CA062491-12, http://linkedlifedata.com/resource/pubmed/grant/U01 CA062491-13, http://linkedlifedata.com/resource/pubmed/grant/U01 CA062491-14, http://linkedlifedata.com/resource/pubmed/grant/U01 CA062491-15, http://linkedlifedata.com/resource/pubmed/grant/U01 CA062491-16, http://linkedlifedata.com/resource/pubmed/grant/U01 CA062491-17, http://linkedlifedata.com/resource/pubmed/grant/U01CA062491, http://linkedlifedata.com/resource/pubmed/grant/UL1 RR025011-01, http://linkedlifedata.com/resource/pubmed/grant/UL1 RR025011-02, http://linkedlifedata.com/resource/pubmed/grant/UL1 RR025011-03, http://linkedlifedata.com/resource/pubmed/grant/UL1 RR025011-03S1, http://linkedlifedata.com/resource/pubmed/grant/UL1 RR025011-03S2, http://linkedlifedata.com/resource/pubmed/grant/UL1 RR025011-04
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1432-0843
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
66
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
973-80
pubmed:dateRevised
2011-1-25
pubmed:meshHeading
pubmed-meshheading:20127092-Adult, pubmed-meshheading:20127092-Aged, pubmed-meshheading:20127092-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:20127092-Camptothecin, pubmed-meshheading:20127092-Chromatography, High Pressure Liquid, pubmed-meshheading:20127092-Dose-Response Relationship, Drug, pubmed-meshheading:20127092-Drug Synergism, pubmed-meshheading:20127092-Female, pubmed-meshheading:20127092-Glucuronosyltransferase, pubmed-meshheading:20127092-Humans, pubmed-meshheading:20127092-Male, pubmed-meshheading:20127092-Maximum Tolerated Dose, pubmed-meshheading:20127092-Middle Aged, pubmed-meshheading:20127092-Neoplasms, pubmed-meshheading:20127092-P-Glycoprotein, pubmed-meshheading:20127092-Polymorphism, Genetic, pubmed-meshheading:20127092-Pyridines, pubmed-meshheading:20127092-Thiosemicarbazones, pubmed-meshheading:20127092-Treatment Outcome
pubmed:year
2010
pubmed:articleTitle
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.
pubmed:affiliation
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI, 53792, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase I, Research Support, N.I.H., Extramural